ATE330620T1 - Verwendung von midkin oder von anti-midkin antikörper - Google Patents

Verwendung von midkin oder von anti-midkin antikörper

Info

Publication number
ATE330620T1
ATE330620T1 AT98931102T AT98931102T ATE330620T1 AT E330620 T1 ATE330620 T1 AT E330620T1 AT 98931102 T AT98931102 T AT 98931102T AT 98931102 T AT98931102 T AT 98931102T AT E330620 T1 ATE330620 T1 AT E330620T1
Authority
AT
Austria
Prior art keywords
midkin
antibodies
midkine
inducible
heparin
Prior art date
Application number
AT98931102T
Other languages
English (en)
Inventor
Takashi Muramatsu
Tohru Takada
Kazuhiro Toriyama
Hisako Muramatsu
Original Assignee
Takashi Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Muramatsu filed Critical Takashi Muramatsu
Application granted granted Critical
Publication of ATE330620T1 publication Critical patent/ATE330620T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT98931102T 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper ATE330620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20533297 1997-07-14
JP20532097 1997-07-14

Publications (1)

Publication Number Publication Date
ATE330620T1 true ATE330620T1 (de) 2006-07-15

Family

ID=26515003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931102T ATE330620T1 (de) 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper

Country Status (10)

Country Link
US (1) US7390491B2 (de)
EP (1) EP0998941B9 (de)
JP (1) JP2010215673A (de)
KR (1) KR100571010B1 (de)
CN (1) CN1287852C (de)
AT (1) ATE330620T1 (de)
AU (1) AU756279B2 (de)
CA (1) CA2296409C (de)
DE (1) DE69835016T2 (de)
WO (1) WO1999003493A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00010110A (es) * 1998-04-17 2002-08-06 Angiogenix Inc Factores angiogenicos terapeuticos y metodos para su uso.
CA2341638C (en) * 1998-08-24 2010-05-11 Meiji Milk Products Co., Ltd. Use of a midkine inhibitor
US20060259026A1 (en) * 2005-05-05 2006-11-16 Baylis Medical Company Inc. Electrosurgical treatment method and device
EP1607102B1 (de) * 2003-03-06 2017-01-18 Medical Therapies Limited Mittel zur prävention von adhäsion nach einer bauchoperation
JP4646070B2 (ja) * 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
UA100847C2 (uk) * 2006-11-14 2013-02-11 Рибомик Инк. Аптамер проти мідкайну і його застосування
EP2803674A3 (de) 2006-11-14 2014-12-24 Medical Therapies Limited Antikörper zur Erkennung der C-Domäne von Midkin
WO2010074218A1 (ja) * 2008-12-25 2010-07-01 株式会社イーベック 抗ヒトミッドカイン抗体
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
WO2014021339A1 (ja) 2012-07-30 2014-02-06 国立大学法人名古屋大学 ヒトミッドカインに対するモノクローナル抗体
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
US5206223A (en) 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
US5210026A (en) 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
CZ232593A3 (en) 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
WO1994028889A1 (en) * 1993-06-08 1994-12-22 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
WO1996024362A1 (fr) 1995-02-07 1996-08-15 Shiseido Company, Ltd. Agents anti-inflammatoires
JPH08277224A (ja) * 1995-02-07 1996-10-22 Shiseido Co Ltd 抗炎症剤
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (ja) 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
EP0937461B1 (de) * 1996-07-10 2005-07-06 Meiji Dairies Corporation Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Also Published As

Publication number Publication date
CN1287852C (zh) 2006-12-06
KR100571010B1 (ko) 2006-04-13
CN1306435A (zh) 2001-08-01
EP0998941A4 (de) 2004-05-12
DE69835016D1 (de) 2006-08-03
AU8131098A (en) 1999-02-10
CA2296409C (en) 2010-05-18
US20030072739A1 (en) 2003-04-17
CA2296409A1 (en) 1999-01-28
WO1999003493A1 (fr) 1999-01-28
EP0998941B1 (de) 2006-06-21
AU756279B2 (en) 2003-01-09
JP2010215673A (ja) 2010-09-30
EP0998941A1 (de) 2000-05-10
US7390491B2 (en) 2008-06-24
EP0998941B9 (de) 2007-03-14
KR20010021814A (ko) 2001-03-15
DE69835016T2 (de) 2007-06-28

Similar Documents

Publication Publication Date Title
DE69835016D1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
ATE454141T1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
DE69941800D1 (de) Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE103932T1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
ATE339505T1 (de) Antagoniste von interleukin-15
ATA98488A (de) Pharmazeutische verwendung von 17-ketosteroiden
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
DE69001839D1 (de) 1-hydroxyvitamin d2-epimer und dessen derivate.
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE3680000D1 (de) Stabilisierte aktive formen von vitamin-d3.
DE69624707D1 (de) Therapeutische verwendung von 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonsäure und ihre salze
ATE208042T1 (de) Hapten-analoge zur verwendung in immunoassays
ATE172721T1 (de) Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
ATE227557T1 (de) Verwendung von zahnpflegemitteln enthaltend bovines kolostrum
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE341293T1 (de) Kortikalknochenimplantat für wirbelfusion nach smith-robinson

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties